Search

Displaying results 4011 - 4020 of 10000 in total
  1. Drug

    MPI-674

    go.drugbank.com/drugs/DB05749
    Experimental

    AIs are a class of drugs that reduce the amount of estrogen circulating in the body by binding to and inhibiting the enzyme aromatase, which is responsible for converting certain hormones to estrogen. … It is developed for the treatment of several serious women’s health conditions including endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding (AUB).

  2. Drug

    MF101

    go.drugbank.com/drugs/DB05052
    Investigational

    MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women. … MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation

  3. Drug

    Jojoba oil

    go.drugbank.com/drugs/DB14252
    Approved

    Jojoba oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Mixtures: GONGFUTOUYANG protein conditioner for
  4. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  5. Drug

    Fluocortolone

    go.drugbank.com/drugs/DB08971
    ApprovedWithdrawn

    Fluocortolone is a glucocorticoid with anti-inflammatory activity used topically for various skin disorders.

    Mixtures: SCHERIPROCT N CREAM, เชริพร็อค(R) เอ็นCategories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Corticosteroids for Systemic Use, Plain
  6. Drug

    Cilostazol

    go.drugbank.com/drugs/DB01166
    ApprovedInvestigational

    Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia … It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.

    Categories: Compounds used in a research, industrial, or household settingProducts: PRAXOCOL X 100 MG, PRAXOCOL TABLETAS X 50 MG
  7. Drug

    Axatilimab

    go.drugbank.com/drugs/DB16388
    ApprovedInvestigational

    [A264309] Axatilimab was approved by the FDA in August 2024 for the third-line treatment of cGVHD. … [L51194] It is targeted against macrophage colony-stimulating factor 1 receptor (CSF-1R), causing a reduction in circulating levels of monocytes and macrophages responsible for the symptoms associated

  8. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55. … JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed.

  9. Drug

    Tegafur-uracil

    go.drugbank.com/drugs/DB09327
    Approved

    It was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA. … Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4.

  10. Drug

    PW2101

    go.drugbank.com/drugs/DB06483
    Experimental

    PW2101 is a beta blocker intended for the treatment of hypertension and angina. … The drug was developed by Penwest Pharmaceuticals and in 2005 the FDA issues a Non-Approval letter due to the degree of kinetic variability of PW2101 observed among individuals.